Researchers find potential for new uses of old drug

(Phys.org) -- Researchers in Canada, Scotland and Australia have discovered that salicylate, the active ingredient in aspirin, directly increases the activity of the protein AMPK (AMP-activated protein kinase), a key player in regulating cell growth and metabolism. AMPK which is considered a cellular fuel-gauge is switched on by exercise and the commonly used anti-diabetic medication metformin.

The research from scientists at McMaster University, the University of Dundee and the University of Melbourne will be published in today's issue of the journal Science.

"We're finding this old dog of already knows new tricks," said Dr. Greg Steinberg, a co-principal investigator of the study. "In the current paper we show that, in contrast to exercise or metformin which increase AMPK activity by altering the cells energy balance, the effects of salicylate is totally reliant on a single Ser108 amino acid of the beta 1 subunit.

"We show that salicylate increases fat burning and reduces liver fat in and that this does not occur in genetically modified mice lacking the beta1 subunit of AMPK," he said. Steinberg is an associate professor of medicine in the Michael G. DeGroote School of Medicine at McMaster University and the Canada Research Chair in Metabolism and Obesity.

These findings are important as a large clinical trial is currently underway testing whether salsalate (a well-tolerated aspirin derivative), can prevent .

Salicylate, which is derived from willow bark, and is the active ingredient in aspirin, is believed to be one of the oldest drugs in the world with first reports of its use dating back to an Egyptian papyrus in 1543 BC.

An anti-inflammatory drug first used as a painkiller more than a century ago, aspirin is now given to people at risk of heart attacks and strokes as well as patients with vascular disease. McMaster scientists played a key role in that previous research.

Three studies published last month in the medical journal The Lancet reported that taking an aspirin every day may significantly reduce the risk of many cancers and prevent tumors from spreading. The unanswered question was how this anti-cancer benefit occurs.

With many recent studies showing that metformin may be important for cancer prevention the authors' study raise the interesting possibility that aspirin may also be working in a similar manner; however, further studies are needed as the concentrations of salicylate used in the current study were higher than the cancer trials. Nonetheless, the researchers' results show the one thing that salicylates and metformin hold in common is their ability to activate AMPK.

Related Stories

AMPK amplifies Huntington's disease

Jul 18, 2011

A new study describes how hyperactivation of AMP-activated protein kinase (AMPK) promotes neurodegeneration in Huntington's disease (HD). The article appears online on July 18, 2011, in The Journal of Cell Biology.

Aspirin may lower the risk of pancreatic cancer

Apr 04, 2011

The use of aspirin at least once per month is associated with a significant decrease in pancreatic cancer risk, according to results of a large case-control study presented at the AACR 102nd Annual Meeting 2011, held here ...

Recommended for you

Determine patient preferences by means of conjoint analysis

15 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments